Powder: -20°C for 3 years | In solvent: -80°C for 1 year
K6PC-5 is a ceramide derivative that acts as an activator of sphingosine kinase 1 (SPHK1), inducing a swift and temporary rise in intracellular calcium levels. With its potential applications in skin diseases associated with abnormal keratinocyte function, as well as in studies on neurodegeneration and virus infection, K6PC-5 presents a promising compound for research purposes.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 34.00 | |
5 mg | In stock | $ 80.00 | |
10 mg | In stock | $ 128.00 | |
25 mg | In stock | $ 289.00 | |
50 mg | In stock | $ 472.00 | |
100 mg | In stock | $ 693.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 89.00 |
Description | K6PC-5 is a ceramide derivative that acts as an activator of sphingosine kinase 1 (SPHK1), inducing a swift and temporary rise in intracellular calcium levels. With its potential applications in skin diseases associated with abnormal keratinocyte function, as well as in studies on neurodegeneration and virus infection, K6PC-5 presents a promising compound for research purposes. |
In vitro | K6PC-5 (1-10 μM; 24 h) increases the involucrin and loricrin levels in a dose-dependent manner in normal human epidermal keratinocytes (NHEKs). K6PC-5 promotes differentiation and proliferation of keratinocytes via intracellular Ca2+ signaling. In addition, K6PC-5 stimulates the phosphorylation of p42/44 extracellular signal-regulated kinase and c-Jun N-terminal kinase[1]. K6PC-5 (1-10 μM; 24 h) promotes fibroblasts proliferation and collagen synthesis in human fibroblasts. K6PC-5 induces intracellular Ca2+ concentration ([Ca2+]i) oscillations in human fibroblasts[2]. K6PC-5 (10, 25, and 50 μM; 48 h) significantly attenuates EBOV-induced infection in EBOV-infected EA.hy926 cells. K6PC-5 significantly reduces the virus titers in supernatants of infected cells and strikingly decreased the amount of VP40 in a concentration-dependent manner[3]. |
In vivo | In intrinsically aged hairless mice (56 weeks old), 1% K6PC-5 is applied topically for 2 weeks. This K6PC-5 treatment significantly increases both the number of dermal fibroblasts and collagen production. As a consequence, dermal thickness also increased significantly[2]. |
Synonyms | K6PC5, K6PC 5 |
Molecular Weight | 343.5 |
Formula | C19H37NO4 |
CAS No. | 756875-51-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 90mg/mL (262mM), sonification is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
K6PC-5 756875-51-1 GPCR/G Protein S1P Receptor K6PC5 K6PC 5 inhibitor inhibit